First clinical study of a pegylated diabody <sup>124</sup>I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers
Andrew M. Scott, Timothy Akhurst, Fook-Thean Lee, Marika Ciprotti, Ian D. Davis, Andrew Weickhardt, Hui Gan, Rodney J. Hicks, Sze Ting Lee, Pece Kocovski, Nancy Guo, Maggie Oh, Linda Mileshkin, Scott Williams, Declan G. Murphy, Kunthi Pathmaraj, Graeme O’Keefe, Sylvia Gong, John S. Pedersen, Fiona E. Scott, Michael Wheatcroft, Peter J. Hudson
Abstract
These data demonstrates the safety and feasibility of using pegylated diabodies for selective tumor imaging and potential delivery of therapeutic payloads in cancer patients.
Topics & Concepts
BiodistributionPharmacokineticsPEGylationPEG ratioImmunogenicityBioavailabilityChemistryPharmacologyMedicineIn vivoNuclear medicinePolyethylene glycolIn vitroAntigenImmunologyBiochemistryBiotechnologyEconomicsBiologyFinanceMonoclonal and Polyclonal Antibodies ResearchPeptidase Inhibition and AnalysisGlycosylation and Glycoproteins Research